Mengyi Li

Mengyi Li

Auto-generated profile, based on publicly available information

Mengyi Li

State Key Laboratory of Respiratory Disease National Clinical Research Center for Respiratory Disease National Center for Respiratory Medicine Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
WLWen Luo
Wen Luo
XSXingxing Su
Xingxing Su
QZQiao Zhang
Qiao Zhang
ZWZhongyu Wang
Zhongyu Wang
ZJZheng Jin
Zheng Jin
BZBo Zhu
Bo Zhu
S100A8/A9 plays a critical role in the formation of an immunosuppressive tumor microenvironment. Therefore, it is important to identify inhibitors targeting S100A8/A9 to enhance antitumor immunity. However, systemic targeting of S100A8/A9 in clinical trials has shown minimal effects. Understanding the reasons underlying this underperformance is important for developing drugs targeting S100A8/A9 that could effectively reverse the immunosuppressive tumor microenvironment. In this study, using hematopoietic system–specific conditional knockout mice in heterotopic models of lung and colon cancer and systemic pharmacological interference, we demonstrated that S100A8/A9 perturbation in the hematopoietic system accelerates tumor progression by attenuating T cell–mediated antitumor immunity. Mechanistically, S100A8/A9 perturbation triggered myeloid-biased differentiation in the bone marrow by promoting the production of abnormal granulocyte-monocyte progenitors. The local release of S100A8/A9 inhibitors using a tumor-targeted drug delivery system exhibited antitumor potential by avoiding myelopoiesis-promoting effects. These findings reveal a mechanism underlying the limited efficacy of systemic S100A8/A9 inhibition and propose a targeted strategy to enhance antitumor effects.

27 September 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
SMShufeng Ma
Shufeng Ma
CKChangyuan Kang
Changyuan Kang
XLXixian Liu
Xixian Liu
LYLichao Yang
Lichao Yang
MLMengyi Li
Mengyi Li
ZYZifeng Yang
Zifeng Yang
Influenza A virus (IAV) commandeers host transcriptional machinery to replicate, but mechanisms remain elusive. CRISPR screen identifies PARP1 as a proviral factor that binds viral NS1. ATAC‑seq reveals IAV drives PARP1‑dependent chromatin remodeling at promoter‑proximal regions (−100 to +300 bp), linking PARP1 to viral RNA synthesis. Mechanistically, NS1 engages PARP1's helical domain (HD), which alone forms large, irregular condensates with low fluidity, acting as a built‑in rheostat. HD deletion confers high droplet mobility, whereas NS1 binding locks PARP1 into a hyper‑condensed, gel‑like state. This phase transition traps Pol II in prolonged pause by enriching pausing factors (SPT5 ‑PLD , NELFA, NELFE) and excluding release factors (SPT5 ‑PRD , AFF4). The paused environment is hijacked for efficient cap‑snatching and viral RNA synthesis. This proviral activity is independent of PARP1's polymerase activity, revealing a non‑canonical mechanism that complements recent reports of PARP1‑mediated antiviral ADP‑ribosylation. Targeting this phase transition, we identify tectochrysin (TEC) and isoferulic acid (IFA), which restore fluidity, reverse pausing, and suppress IAV in mice and lung organoids without toxicity. Our work establishes that NS1 coopts PARP1 phase separation via the HD rheostat to prolong transcriptional pausing, introducing ‘phase transition correction’ as an antiviral paradigm.